# reload+after+2024-01-21 01:47:15.108794
address1§72 Hammersmith Road
city§London
zip§W14 8TH
country§United Kingdom
phone§44 20 3457 6900
website§https://www.silence-therapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's mRNAi GOLD GalNAc Oligonucleotide Discovery platform that is used to target specific disease-associated genes in the liver. Its siRNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company develops SLN360, which is in phase 2 clinical development to reduce high levels of lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform, as well as the company also collab with Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
fullTimeEmployees§122
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Craig A. Tooman M.B.A.', 'age': 57, 'title': 'President & Chief Executive Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 827060, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Rhonda L. Hellums', 'age': 51, 'title': 'Chief Financial Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 557311, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Steven J. Romano M.D.', 'age': 64, 'title': 'Head of Research & Development', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 47079, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Marie Wikstrom Lindholm Ph.D.', 'title': 'Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Gem Gokmen Hopkins', 'title': 'Head of IR & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Barbara A. Ruskin J.D., Ph.D.', 'age': 63, 'title': 'Senior VP and Chief Intellectual Property & Innovation Officer', 'yearBorn': 1960, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Eric  Floyd M.B.A., M.S., Ph.D.', 'age': 61, 'title': 'Senior Vice President of Regulatory Affairs & Quality Assurance', 'yearBorn': 1962, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. J.P.  Gabriel', 'title': 'Chief Technical Operations Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Curtis  Rambaran M.D.', 'title': 'Chief Medical Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.409
priceToSalesTrailing12Months§24.71255
currency§USD
dateShortInterest§1702598400
exchange§NGM
quoteType§EQUITY
shortName§Silence Therapeutics Plc - Amer
longName§Silence Therapeutics plc
firstTradeDateEpochUtc§1599571800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§4f883c73-882c-3ad5-b0b1-cc065f9f5e86
gmtOffSetMilliseconds§-18000000
targetHighPrice§75.37
targetLowPrice§26.13
targetMeanPrice§43.55
targetMedianPrice§29.14
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§4.234
grossMargins§0.54242
ebitdaMargins§-1.6732601
trailingPegRatio§None
